Available treatment options for dystonia

References

• Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics. 2014 Jan;11(1):139–152.
   Google Scholar
• Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013 Jun 15;28(7):863–873.
   Google Scholar
• Albanese A, Bhatia K, DeLong MR, et al. “Complex” dystonia is not a category in the new 2013 consensus classification. Mov Disord. 2016 Nov;31(11):1758–1759.
   Google Scholar
• Berman BD, Jinnah HA. Dystonia: five new things. Neurol Clin Pract. 2015 Jun;5(3):232–240.
   Google Scholar
• Camargos S, Cardoso F. Understanding dystonia: diagnostic issues and how to overcome them. Arq Neuropsiquiatr. 2016 Nov;74(11):921–936.
   Google Scholar
• Shakkottai VG, Batla A, Bhatia K, et al. Current opinions and areas of consensus on the role of the cerebellum in dystonia. Cerebellum. 2017 Apr;16(2):577–594.
   Google Scholar
• Pietracupa S, Bruno E, Cavanna AE, et al. Scales for hyperkinetic disorders: a systematic review. J Neurol Sci. 2015 Nov 15;358(1–2):9–21.
   Google Scholar
• Pirio Richardson S, Wegele AR, Skipper B, et al. Dystonia treatment: patterns of medication use in an international cohort. Neurology. 2017 Feb 7;88(6):543–550.
   Google Scholar
• Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol. 2014 Jan;13(1):100–112.
   Google Scholar
• Berman BD, Junker J, Shelton E, et al. Psychiatric associations of adult-onset focal dystonia phenotypes. J Neurol Neurosurg Psychiatry. 2017 Apr 24.
   Google Scholar
• Patel N, Hanfelt J, Marsh L, et al. Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):882–884.
   Google Scholar
• Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology. 1986 Feb;36(2):160–164.
   Google Scholar
• Taylor AE, Lang AE, Saint-Cyr JA, et al. Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies. Clin Neuropharmacol. 1991 Feb;14(1):62–77.
   Google Scholar
• Fahn S. High dosage anticholinergic therapy in dystonia. Neurology. 1983 Oct;33(10):1255–1261.
   Google Scholar
• Lumsden DE, Kaminska M, Tomlin S, et al. Medication use in childhood dystonia. Eur J Paediatr Neurol. 2016 Jul;20(4):625–629.
   Google Scholar
• Rice J, Waugh M-C. Pilot study on trihexyphenidyl in the treatment of dystonia in children with cerebral palsy. J Child Neurol. 2009 Feb;24(2):176–182.
   Google Scholar
• Truong DD, Sandroni P, van den Noort S, et al. Diphenhydramine is effective in the treatment of idiopathic dystonia. Arch Neurol. 1995 Apr;52(4):405–407.
   Google Scholar
• Greene PE, Fahn S. Baclofen in the treatment of idiopathic dystonia in children. Mov Disord. 1992;7(1):48–52.
   Google Scholar
• Narayan RK, Loubser PG, Jankovic J, et al. Intrathecal baclofen for intractable axial dystonia. Neurology. 1991 Jul;41(7):1141–1142.
   Google Scholar
• Albright AL, Barry MJ, Shafton DH, et al. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol. 2001 Oct;43(10):652–657.
   Google Scholar
• Motta F, Antonello CE. Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience. J Neurosurg Pediatr. 2014 Mar;13(3):301–306.
   Google Scholar
• Albright AL, Ferson SS. Intraventricular baclofen for dystonia: techniques and outcomes. Clinical article. J Neurosurg Pediatr. 2009 Jan;3(1):11–14.
   Google Scholar
• Turner M, Nguyen HS, Cohen-Gadol AA. Intraventricular baclofen as an alternative to intrathecal baclofen for intractable spasticity or dystonia: outcomes and technical considerations. J Neurosurg Pediatr. 2012 Oct;10(4):315–319.
   Google Scholar
• Wijemanne S, Jankovic J. Dopa-responsive dystonia–clinical and genetic heterogeneity. Nat Rev Neurol. 2015 Jul;11(7):414–424.
   Google Scholar
• Yaltho TC, Jankovic J, Lotze T. The association of Tourette syndrome and dopa-responsive dystonia. Mov Disord. 2011 Feb 1;26(2):359–360.
   Google Scholar
• Trender-Gerhard I, Sweeney MG, Schwingenschuh P, et al. Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):839–845.
   Google Scholar
• Cai C, Shi W, Zeng Z, et al. GTP cyclohydrolase I and tyrosine hydroxylase gene mutations in familial and sporadic dopa-responsive dystonia patients. PLoS One. 2013;8(6):e65215.
   Google Scholar
• Schiller A, Wevers RA, Steenbergen GC, et al. Long-term course of L-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency. Neurology. 2004 Oct 26;63(8):1524–1526.
   Google Scholar
• Friedman J, Roze E, Abdenur JE, et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol. 2012 Apr;71(4):520–530.
   Google Scholar
• Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016 Dec;17(18):2461–2470.
   Google Scholar
• Kang UJ, Burke RE, Fahn S. Tardive dystonia. Adv Neurol. 1988;50:415–429.
   Google Scholar
• Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982 Dec;32(12):1335–1346.
   Google Scholar
• Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb;48(2):358–362.
   Google Scholar
• Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol. 1982 Jan;11(1):41–47.
   Google Scholar
• Miguel R, Mendonça MD, Barbosa R, et al. Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study. Ther Adv Neurol Disord. 2017 Feb;10(2):81–90.
   Google Scholar
• Kenney C, Hunter C, Davidson A, et al. Short-term effects of tetrabenazine on chorea associated with Huntington’s disease. Mov Disord. 2007 Jan;22(1):10–13.
   Google Scholar
• Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017 May 23;88(21):2003–2010.
   Google Scholar
• Grigoriadis DE, Smith E, Hoare SRJ, et al. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017 Jun;361(3):454–461.
   Google Scholar
• Lucetti C, Bellini G, Nuti A, et al. Treatment of patients with tardive dystonia with olanzapine. Clin Neuropharmacol. 2002 Mar–Apr;25(2):71–74.
   Google Scholar
• Seeman P. Clozapine, a fast-off-D2 antipsychotic. ACS Chem Neurosci. 2014 Jan 15;5(1):24–29.
   Google Scholar
• Hanagasi HA, Bilgic B, Gurvit H, et al. Clozapine treatment in oromandibular dystonia. Clin Neuropharmacol. 2004 Mar–Apr;27(2):84–86.
   Google Scholar
• Karp BI, Goldstein SR, Chen R, et al. An open trial of clozapine for dystonia. Mov Disord. 1999 Jul;14(4):652–657.
   Google Scholar
• Thiel A, Dressler D, Kistel C, et al. Clozapine treatment of spasmodic torticollis. Neurology. 1994 May;44(5):957–958.
   Google Scholar
• Liow NY, Gimeno H, Lumsden DE, et al. Gabapentin can significantly improve dystonia severity and quality of life in children. Eur J Paediatr Neurol. 2016 Jan;20(1):100–107.
   Google Scholar
• Lerose M, Di Fabio R, Serrao M, et al. Gabapentin can improve dystonia in confirmed Wilson disease. Can J Neurol Sci. 2014 Mar;41(2):284–285.
   Google Scholar
• Lal S. Improvement in spasmodic torticollis following treatment and withdrawal from high dose lorazepam–clinical observations. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(3–4):531–535.
   Google Scholar
• Martinez-Ramirez D, Paz-Gomez V, Rodriguez RL. Response to zolpidem in oromandibular dystonia: a case report. Parkinsonism Relat Disord. 2015 Feb;21(2):154–155.
   Google Scholar
• Miyazaki Y, Sako W, Asanuma K, et al. Efficacy of zolpidem for dystonia: a study among different subtypes. Front Neurol. 2012;3:58.
   Google Scholar
• Vijayakumar D, Wijemanne S, Jankovic J. Treatment of blepharospasm with apraclonidine. J Neurol Sci. 2017 Jan 15;372:57–59.
   Google Scholar
• Frucht SJ, Bordelon Y, Houghton WH, et al. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord. 2005 Oct;20(10):1330–1337.
   Google Scholar
• Hainque E, Vidailhet M, Cozic N, et al. A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. Neurology. 2016 May 3;86(18):1729–1735.
   Google Scholar
• Pirio Richardson S, Altenmüller E, Alter K, et al. Research priorities in limb and task-specific dystonias. Front Neurol. 2017;8:170.
   Google Scholar
• Jankovic J. Botulinum toxin: state of the art. Mov Disord. Forthcoming 2017.
   Google Scholar
• Jankovic J. Botulinum toxin in the treatment of dystonia and other disorders. In: Current Neurology. Mosby-Year Book, Inc; 1994. p. 207–229.
   Google Scholar
• Ramirez-Castaneda J, Jankovic J, Comella C, et al. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013 Nov;28(13):1775–1783.
   Google Scholar
• Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2016 May 10;86(19):1818–1826.
   Google Scholar
• Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987 Apr;37(4):616–623.
   Google Scholar
• Truong D, Comella C, Fernandez HH, et al. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008;14(5):407–414.
   Google Scholar
• Jankovic J, Comella C, Hanschmann A, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011 Jul;26(8):1521–1528.
   Google Scholar
• Nüssgens Z, Roggenkämper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997 Apr;235(4):197–199.
   Google Scholar
• Roggenkämper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm (Vienna). 2006 Mar;113(3):303–312.
   Google Scholar
• Wabbels B, Reichel G, Fulford-Smith A, et al. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm (Vienna). 2011 Feb;118(2):233–239.
   Google Scholar
• Saad J, Gourdeau A. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique. J Neuroophthalmol. 2014 Sep;34(3):233–236.
   Google Scholar
• Greene P, Kang U, Fahn S, et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990 Aug;40(8):1213–1218.
   Google Scholar
• Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):13–17.
   Google Scholar
• Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul;20(7):783–791.
   Google Scholar
• Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun;16(5):316–323.
   Google Scholar
• Comella CL, Jankovic J, Truong DD, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15;308(1–2):103–109.
   Google Scholar
• Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997 Sep;49(3):701–707.
   Google Scholar
• Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999 Oct 22;53(7):1439–1446.
   Google Scholar
• Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431–1438.
   Google Scholar
• Charles D, Brashear A, Hauser RA, et al. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012 Sep–Oct;35(5):208–214.
   Google Scholar
• Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):6–12.
   Google Scholar
• Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005 Jun 14;64(11):1949–1951.
   Google Scholar
• Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005 Nov 8;65(9):1423–1429.
   Google Scholar
• Pappert EJ, Germanson T, Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008 Mar 15;23(4):510–517.
   Google Scholar
• Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope. 2015 Aug;125(8):1751–1757.
   Google Scholar
• Cole R, Hallett M, Cohen LG. Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Mov Disord. 1995 Jul;10(4):466–471.
   Google Scholar
• Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, et al. Botulinum toxin for writer’s cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry. 2007 Mar;78(3):264–270.
   Google Scholar
• Jankovic J. New uses of botulinum toxin in movement disorders. Toxicon. Forthcoming 2017.
   Google Scholar
• Schneider SA, Dusek P, Hardy J, et al. Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Curr Neuropharmacol. 2013 Jan;11(1):59–79.
   Google Scholar
• Hogarth P. Neurodegeneration with brain iron accumulation: diagnosis and management. J Mov Disord. 2015 Jan;8(1):1–13.
   Google Scholar
• Tello C, Darling A, Lupo V, et al. On the complexity of clinical and molecular bases of neurodegeneration with brain iron accumulation. Clin Genet. 2017 May 23. doi: 10.1111/cge.13057. [Epub ahead of print].
   Google Scholar
• Waln O, Jankovic J. Paroxysmal movement disorders. Neurol Clin. 2015 Feb;33(1):137–152.
   Google Scholar
• Erro R, Sheerin U-M, Bhatia KP. Paroxysmal dyskinesias revisited: a review of 500 genetically proven cases and a new classification. Mov Disord. 2014 Aug;29(9):1108–1116.
   Google Scholar
• Termsarasab P, Frucht SJ. Dystonic storm: a practical clinical and video review. J Clin Mov Disord. 2017;4:10.
   Google Scholar
• Mariotti P, Fasano A, Contarino MF, et al. Management of status dystonicus: our experience and review of the literature. Mov Disord. 2007 May 15;22(7):963–968.
   Google Scholar
• Pouclet-Courtemanche H, Rouaud T, Thobois S, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology. 2016 Feb 16;86(7):651–659.
   Google Scholar
• Azoulay-Zyss J, Roze E, Welter M-L, et al. Bilateral deep brain stimulation of the pallidum for myoclonus-dystonia due to ε-sarcoglycan mutations: a pilot study. Arch Neurol. 2011 Jan;68(1):94–98.
   Google Scholar
• Vidailhet M, Vercueil L, Houeto J-L, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med. 2005 Feb 3;352(5):459–467.
   Google Scholar
• Vidailhet M, Vercueil L, Houeto J-L, et al. Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study. Lancet Neurol. 2007 Mar;6(3):223–229.
   Google Scholar
• Kupsch A, Benecke R, Müller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med. 2006 Nov 9;355(19):1978–1990.
   Google Scholar
• Volkmann J, Wolters A, Kupsch A, et al. Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurol. 2012 Dec;11(12):1029–1038.
   Google Scholar
• Reese R, Gruber D, Schoenecker T, et al. Long-term clinical outcome in meige syndrome treated with internal pallidum deep brain stimulation. Mov Disord. 2011 Mar;26(4):691–698.
   Google Scholar
• Baizabal Carvallo JF, Mostile G, Almaguer M, et al. Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations. Stereotact Funct Neurosurg. 2012;90(5):300–306.
   Google Scholar
• Schjerling L, Hjermind LE, Jespersen B, et al. A randomized double-blind crossover trial comparing subthalamic and pallidal deep brain stimulation for dystonia. J Neurosurg. 2013 Dec;119(6):1537–1545.
   Google Scholar
• Ostrem JL, San Luciano M, Dodenhoff KA, et al. Subthalamic nucleus deep brain stimulation in isolated dystonia: A 3-year follow-up study. Neurology. 2017 Jan 3;88(1):25–35.
   Google Scholar
• Ondo WG, Desaloms JM, Jankovic J, et al. Pallidotomy for generalized dystonia. Mov Disord. 1998 Jul;13(4):693–698.
   Google Scholar
• Elias WJ. A trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2016 Dec 1;375(22):2202–2203.
   Google Scholar
• Dallapiazza RF, Timbie KF, Holmberg S, et al. Noninvasive neuromodulation and thalamic mapping with low-intensity focused ultrasound. J Neurosurg. 2017;21:1–10.
   Google Scholar